Article

Phone calls, customized materials of limited value for glaucoma medication adherence

The use of telephone calls and customized printed materials may be of limited value in improving medication adherence in patients with glaucoma, according to results of a randomized, controlled clinical trial published online by the Archives of Ophthalmology.

Philadelphia-The use of telephone calls and customized printed materials may be of limited value in improving medication adherence in patients with glaucoma, according to results of a randomized, controlled clinical trial published online by the Archives of Ophthalmology.

Karen Glanz, PhD, MPH, of the University of Pennsylvania, Philadelphia, and colleagues enrolled 312 patients with glaucoma in the trial at two eye clinics at a Veterans Affairs Medical Center and a large public hospital. The patients (average age: nearly 63 years) were considered to be nonadherent because they did not take their medication, refill their prescriptions, and/or keep their medical appointments.

The treatment group received automated, interactive telephone calls and tailored printed materials, whereas the control group received usual care, which included the recommendation for medical appointments and prescription refills. Researchers measured adherence to medication-taking, prescription-refilling, and appointment-keeping based on interviews, medical charts, and other data.

“A statistically significant increase for all adherence measures was noted in both the treatment group and the control group in the I-SIGHT (Interactive Study to Increase Glaucoma Adherence to Treatment) trial. The treatment group had greater improvements in adherence in four of six categories, but this did not reach statistical significance,” the authors commented.

Researchers suggest that “motivated patients” in an ongoing clinical trial might improve their adherence to treatment even without customized messages for encouragement.

“New technologies, such as interactive voice recognition and electronic reminder devices, may play a supportive role in the effort to improve adherence in patients with glaucoma, but further study is warranted,” the authors concluded.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.